CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Nitric Oxide-Releasing DrugWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1151 INC424 / Ruxolitinib Wiki 1.00

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Multi-Center, Double-Blinded, Placebo-Controlled, Phase II Clinical Efficacy Study Evaluating NORS To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Mild COVID-19

This is a multi-center, double-blinded, placebo-controlled parallel, phase II clinical efficacy study evaluating NORS for the treatment of COVID-19 in individuals with Suspected mild COVID-19 Infection.

NCT04443868 SARS-CoV Infection Drug: Nitric Oxide-Releasing Drug
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Number of subjects requiring hospitalization or ER/ED visits for COVID-19/flu-like symptoms in NORS vs placebo group

Measure: To Measure the efficacy of NORS compared to saline placebo in the hospitalization of participants with mild COVID-19 infection

Time: 28 Days

Secondary Outcomes

Description: Measure the change in mean Modified Jackson Cold Score Diary Score

Measure: To Measure reduction of clinical symptoms as compared to saline placebo in participants with mild COVID-19 infection

Time: 7, 14, 21 and 28 days

Description: Number of participants lost-to-follow-up,discontinuing study treatment or number of treatments due to intolerance

Measure: To measure the tolerance of NORS compared to saline placebo in participants with mild COVID-19 infection

Time: 14 days

Description: Severity and frequency of adverse events, pain, discomfort or discontinuations of treatment.

Measure: To measure the tolerance of NORS compared to saline placebo in participants with mild COVID-19 infection

Time: 14 days


No related HPO nodes (Using clinical trials)